Canaccord Genuity Calls DexCom (DXCM) Quarter Solid, Says Momentum Building

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

Canaccord Genuity maintained a Buy rating on DexCom (NASDAQ: DXCM) with an adjusted price target of $19.00 (from $20).

Commenting on the company’s quarterly results, analyst William J. Plovanic said "Net, net we believe Q3/12 was a solid quarter with DexCom continuing to build momentum with patients and physicians. The approval of the Gen4 Platinum sensor marks a major new product cycle and opportunity for top and bottom line growth in 2013."

Plovanic pointed out that management reiterated its positive tone with regards to commercialization of Gen4 Platinum

For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.

Shares of DexCom closed at $13.07 yesterday, with a 52 week range of $6.75-$15.48.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
• Janney Capital Trims Numbers on Buckle (BKE), Margins Peaking
• Wedbush Downgrades salesforce.com (CRM) to Neutral

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Canaccord Genuity

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?